References
- Quiney C, Billard C, Faussat A -M, Salanoubat C, Kolb J -P. Hyperforin inhibits P-gp and BCRP activities in chronic lymphocytic leukaemia cells and myeloid cells. Leuk Lymphoma 2007; 48: 1587–1599
- Steiner H, Polliack A, Kimchi-Sarfaty C, Libster D, Fibach E, Rund D. Differences in rhodamine-123 efflux in B-type chronic lymphocytic leukemia suggest possible gender and stage variations in drug-resistance gene activity. Ann Hematol 1998; 76: 189–194
- Quiney C, Billard C, Salanoubat C, Fourneron J D, Kolb J P. Hyperforin, a new lead compound against the progression of cancer and leukemia?. Leukemia 2006; 20: 1519–1525
- Tian R, Koyabu N, Morimoto S, Shoyama Y, Ohtani H, Sawada Y. Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line. Drug Metab Dispos 2005; 33: 547–554
- Tirona R G, Bailey D G. Herbal product-drug interactions mediated by induction. Br J Clin Pharmacol 2006; 61: 677–681
- Krusekopf S, Roots I. St. John's wort and its constituent hyperforin concordantly regulate expression of genes encoding enzymes involved in basic cellular pathways. Pharmacogenet Genomics 2005; 15: 817–829